This may answer a question I had as to why CEGE, John Hopkins or Harvard were not testing GVAX in colon cancer, a seemingly high priority target, when it is in clinical testing for prostate, breast and ovarian cancers, as well as melanoma and leukemia, wth preclinical testing for lung cancer just being completed. As I understand the Onyvax therapy, cancer cells are harvested from each patient processed and then injected interdermally with BCG to stimulate an immune response. BCG is derived from TB and is presently FDA approved for use in bladder cancer. Not elegant or inexpensive, but if it works...
CEGE is supposed to report on an early bladder cancer trial this year using its oncolytic virus therapy, which they picked up from Novartis.
